← All indications
Ventricular Dysfunction
A condition in which HEART VENTRICLES exhibit impaired function.
Subtype terms (2)
More specific conditions that are subtypes of Ventricular Dysfunction in the MeSH hierarchy.
- Ventricular Dysfunction, Left
40 drugs (34 approved, 6 experimental)
- Ventricular Dysfunction, Right
22 drugs (18 approved, 4 experimental)
Drugs by status
Phase 4 trials (6)
Phase 3 trials (2)
Phase 2 trials (1)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (25)
- Bristol-Myers Squibb
- Gilead Sciences
- AstraZeneca
- Novartis
- Alexion
- National Center for Research Resources (NCRR)
- University of Arizona
- Boston University
- Case Western Reserve University
- Cedars-Sinai Medical Center
- Danderyds Hospital
- Northwell Health
- Postgraduate Institute of Medical Education and Research
- University of Bern
- Tel Aviv University
- University of Ulsan
- Technion University
- University of Nice Sophia Antipolis
- General Electric
- H2O Clinical LLC
- University of Grenoble
- University of Texas, Arlington
- IQVIA
- The University of Texas, Dallas
- Medical Center Leeuwarden
Organization Involved with Phase 3 Indications (18)
- Amgen
- Servier
- Merck
- Biosyn
- Mallinckrodt
- Menarini Group
- Andalusian Initiative for Advanced Therapies
- University of London
- Duke University
- RWTH Aachen University
- Aspirus Heart and Vascular Institute-Research and Education
- University of Cape Town
- Momentum Research, Inc.
- University of Barcelona
- University and Emergency Hospital Bucharest, Romania
- European Union
- Andalusian Initiative in Advanced Therapies
- Universidad Carlos III Madrid
Organization Involved with Phase 2 Indications (27)
- Actelion
- Daiichi Sankyo
- Astellas
- Bayer
- Capricor Inc.
- Quantum Genomics SA
- The EMMES Corporation
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Johns Hopkins University
- McMaster University
- Thomas Jefferson University
- University of Miami
- University of Toronto
- Icahn School of Medicine at Mount Sinai
- University of Amsterdam
- University of Toulouse
- Cardiovascular Cell Therapy Research Network
- Sorbonne University
- University of Texas at Houston
- University of Nantes
- CV Ventures
- University of Perugia
- California Institute for Regenerative Medicine
- The Interuniversity Cardiology Institute of the Netherlands
- Government of France
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (3)